Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Novel CD4 + CD8 + Umbilical Cord Blood Regulatory T Cells

Meixian Huang, Amit Verma, MBBS, Ke Zeng, MD PhD, Mi-Ae Lyu, PhD, Mitsutaka Nishimoto, MD PhD, Hongbing Ma, MD PhD, Zheng Yin, PhD, Swaminathan P. Iyer, MD, Simrit Parmar, MBBS

Blood (2019) 134 (Supplement_1): 4446.

https://doi.org/10.1182/blood-2019-131948

Published: 2019

Journal Articles

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

Yanika Jindamai, MD, Ekarat Rattarittamrong, MD, Arintaya Phrommintikul, MD, Lalita Yongsmith, MD, Thanawat Rattanathammethee, MD, Chatree Chai-Adisaksopha, MD PhD, Adisak Tantiworawit, MD, Lalita Norasetthada, MD

Blood (2019) 134 (Supplement_1): 5390.

https://doi.org/10.1182/blood-2019-126599

Published: 2019

Journal Articles

Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Patients: Prospective Study

Olga Novosad, PhD MD, Oleksandr Gorbach, PhD, Oksana Skachkova, PhD, Ian Pastushenko, MD, Kateryna Ulianchenko, MD, Nataliia Khranovska, PhD, Tetiana Skrypets, MD, Irina Kryachok, Professor

Blood (2019) 134 (Supplement_1): 5232.

https://doi.org/10.1182/blood-2019-130852

Published: 2019

Journal Articles

Prognostic Assessment of the PET-CT Role in Primary Patients with Hodgkin Lymphoma: Do We Still Need More Data?

Olga Novosad, PhD MD, Tetiana Skrypets, MD, Ian Pastushenko, MD, Oleksandr Gorbach, PhD, Andrij Ashykhmin, MD, Yaroslav Kmetyuk, MD, Olga Karpova, MD, Larisa Mykhalska, MD, Olga Kindrakevych, MD, Viktor Kozlov, MD, Mykola Novikov, MD, Viktoriia Kosinova, MD PhD, Olena Oliinichenko, MD, Nina Kostiukova, MD PhD, Oksana Tkachenko, MD PhD, Oksana Karnabeda, MD PhD, Viktoriya Stratienko, MD, Iryna Kriachok, Professor

Blood (2018) 132 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2018-99-118397

Published: 2018

Journal Articles

Extracellular Vesicles: Overview and Clinical Implications

Francoise Dignat-George

Blood (2018) 132 (Supplement 1): SCI-25.

https://doi.org/10.1182/blood-2018-99-109472

Published: 2018

Journal Articles

Composition of Classical Hodgkin Lymphoma Microenvironment Is Associated with Clinical Outcome

Olga Novosad, PhD MD, Tetiana Skrypets, MD, Nataliia Svergun, PhD, Oksana Skachkova, PhD, Oleksandr Gorbach, PhD, Nataliia Khranovska, PhD, Mykhailo Krotevych, PhD MD, Larisa Skoroda, MD, Maryna Koshubarova, MD, Dmitry Novikov, MD, Iryna Kriachok, Professor

Blood (2018) 132 (Supplement 1): 5313.

https://doi.org/10.1182/blood-2018-99-118987

Published: 2018

Journal Articles

The Pros and Cons of Splenectomy in Transfusion Dependent Thalassemia Patient

Adisak Tantiworawit, MD, Somying Dumnil, MD, Nichanan Osataphan, MD, Thanawat Rattanathammethee, MD, Sasinee Hantrakool, MD, Chatree Chai-Adisaksopha, MD, Ekarat Rattarittamrong, MD, Lalita Norasetthada, MD, Pimlak Charoenkwan, MD

Blood (2018) 132 (Supplement 1): 4901.

https://doi.org/10.1182/blood-2018-99-111684

Published: 2018

Journal Articles

Investigation-Based Drug Value Framework in Hodgkin Lymphoma

Ohad Oren, MD

Blood (2018) 132 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2018-99-109708

Published: 2018

Journal Articles

Cardiorenal Syndrome in Thalassemia Patients

Sorasak Makmettakul, MD, Adisak Tantiworawit, MD, Suree Lekawanvijit, MD, Arintaya Phrommintikul, MD, Thanawat Rattanathammethee, MD, Sasinee Hantrakool, MD, Chatree Chai-Adisaksopha, MD, Ekarat Rattarittamrong, MD, Lalita Norasetthada, MD

Blood (2017) 130 (Supplement 1): 3507.

https://doi.org/10.1182/blood.V130.Suppl_1.3507.3507

Published: 2017

Journal Articles

In Vitro Generation of Human Pluripotent Stem Cell-Derived T Cells for Immunotherapy

Amélie Montel-Hagen, PhD, Christopher S. Seet, MD, Suwen Li, Brent Chick, Patrick Chang, Yuhua Zhu, Chongbin He, Shawn Lopez, Gay M. Crooks, MD

Blood (2017) 130 (Supplement 1): 691.

https://doi.org/10.1182/blood.V130.Suppl_1.691.691

Published: 2017

Journal Articles

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Emir Hadzijusufovic, DVM, Gregor Hoermann, MD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Bernd Jilma, MD, Gerit H. Schernthaner, MD, Peter Valent, MD

Blood (2017) 130 (Supplement 1): 1619.

https://doi.org/10.1182/blood.V130.Suppl_1.1619.1619

Published: 2017

Journal Articles

Interim-PET As a Predictive Factor in Patients with Hodgkin's Lymphoma

Blood (2017) 130 (Supplement 1): 5186.

https://doi.org/10.1182/blood.V130.Suppl_1.5186.5186

Published: 2017

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD

Blood (2016) 128 (22): 1856.

https://doi.org/10.1182/blood.V128.22.1856.1856

Published: 2016

Journal Articles

In Vivo Deletion of the Cebpa +37 Kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis

Alan D. Friedman, MD, Hong Guo, MD PhD, Stacy Cooper, MD

Blood (2015) 126 (23): 1178.

https://doi.org/10.1182/blood.V126.23.1178.1178

Published: 2015

Journal Articles

Role of P53 on T Lymphopoisis from Human Embryonic Stem Cells

Jiyuan Liao, PhD, Hiroshi Kohara, PhD, Yoko Nagai, Tomotoshi Marumoto, MD PhD, Kenzaburo Tani, MD PhD

Blood (2015) 126 (23): 4830.

https://doi.org/10.1182/blood.V126.23.4830.4830

Published: 2015

Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani

Blood (2015) 126 (23): 4040.

https://doi.org/10.1182/blood.V126.23.4040.4040

Published: 2015

Journal Articles

Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Katia B.B. Pagnano, MD PhD, Paola Morelato Assunção, MD, Roberto Zullli, Marcia T Delamain, MD, Gislaine OLIVEIRA Duarte, Irene Lorand-Metze, MD PhD, Carmino A De Souza, Sr., MD PhD

Blood (2015) 126 (23): 4031.

https://doi.org/10.1182/blood.V126.23.4031.4031

Published: 2015

Journal Articles

Comparative Analysis of Tyrosine Kinase Inhibitors-Related Pulmonary Hypertension in the Patients Treated By Imatinib, Dasatinib and Nilotinib

Mariko Minami, MD, Toshihiro Miyamoto, MD PhD, Takeshi Arita, MD PhD, Tomohiko Kamimura, MD PhD, Junichiro Yuda, MD, Yoshikane Kikushige, MD PhD, Yasuo Mori, MDPhD, Goichi Yoshimoto, MD PhD, Kenjiro Kamezaki, MD PhD, Koji Kato, MD PhD, Motoaki Shiratsuchi, MDPhD, Katsuto Takenaka, MD PhD, Hiromi Iwasaki, MDPhD, Satoshi Yamasaki, MD PhD, Tsuyoshi Muta, MD PhD, Kazuki Tanimoto, MD PhD, Ryosuke Ogawa, MD PhD, Tetsuya Eto, MD PhD, Koichi Akashi, MD PhD

Blood (2015) 126 (23): 1583.

https://doi.org/10.1182/blood.V126.23.1583.1583

Published: 2015

Journal Articles

Unravelling the Mirnome of MLL -Rearranged Acute Lymphoblastic Leukemia

Patricia Garrido Castro, PhD, Clara Bueno, PhD, Eddy HJ van Roon, PhD, Sandra S Mimoso Pinhancos, MSc, Pauline Schneider, BSc, Merel Willekes, BSc, Pablo Menendez, PhD, Rob Pieters, MD PhD, Ronald Stam, PhD

Blood (2014) 124 (21): 878.

https://doi.org/10.1182/blood.V124.21.878.878

Published: 2014

NARROW

Novel CD4 + CD8 + Umbilical Cord Blood Regulatory T Cells

Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University

Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Patients: Prospective Study

Prognostic Assessment of the PET-CT Role in Primary Patients with Hodgkin Lymphoma: Do We Still Need More Data?

Extracellular Vesicles: Overview and Clinical Implications

Composition of Classical Hodgkin Lymphoma Microenvironment Is Associated with Clinical Outcome

The Pros and Cons of Splenectomy in Transfusion Dependent Thalassemia Patient

Investigation-Based Drug Value Framework in Hodgkin Lymphoma

Cardiorenal Syndrome in Thalassemia Patients

In Vitro Generation of Human Pluripotent Stem Cell-Derived T Cells for Immunotherapy

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Interim-PET As a Predictive Factor in Patients with Hodgkin's Lymphoma

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

In Vivo Deletion of the Cebpa +37 Kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis

Role of P53 on T Lymphopoisis from Human Embryonic Stem Cells

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Comparative Analysis of Tyrosine Kinase Inhibitors-Related Pulmonary Hypertension in the Patients Treated By Imatinib, Dasatinib and Nilotinib

Unravelling the Mirnome of MLL -Rearranged Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only